Billerica, MA, January 8, 2026 (Business Wire) -- Quanterix Corporation appointed Everett Cunningham as President and Chief Executive Officer, effective January 19, 2026, as part of a planned leadership transition. Cunningham joins from Illumina, where he served as Chief Commercial Officer, following earlier commercial leadership roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer. The company said it expects to exceed its full-year 2025 revenue and cash g

Boston, MA, January 9, 2026 (PRNewswire) -- Haemonetics Corporation announced the acquisition of Vivasure Medical Limited, a Galway-based medtech company developing next-generation percutaneous vessel closure technology. Vivasure’s PerQseal® Elite system uses a fully bioabsorbable, suture-free patch to close large-bore access sites and has already secured CE Mark approval in Europe, with a U.S. FDA PMA submission completed in 2025. The deal includes €100 million in upfront

Melville, NY, January 12, 2026 (Business Wire) -- Henry Schein, Inc. announced the appointment of Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026, at which point he will also join the Board of Directors. Lowery succeeds Stanley M. Bergman, who will step down after 35 years as CEO and continue as Chairman to support a smooth leadership transition. Lowery brings more than 20 years of healthcare distribution and operational leadership experience, most r

Indianapolis, IN, January 7, 2026 (PR Newswire) -- Eli Lilly and Company announced it will acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, expanding its presence in inflammatory-mediated diseases. The deal brings Ventyx’s clinical-stage portfolio of oral small molecules, including NLRP3 inhibitors designed to address chronic inflammation across cardiometabolic, neurodegenerative, and autoimmune conditions. Lilly will pay $14.00 pe

Tel Aviv and Boston, MA, December 18, 2025 (Business Wire) -- Syremis Therapeutics debuted with a $165 million Series A financing to develop best-in-class medicines for severe mental health conditions, led by Dexcel Pharma and Third Rock Ventures. The funding will support clinical proof of concept for ST-905, a dual M1/M4 muscarinic agonist already in Phase 1 for schizophrenia, and advance ST-901, a novel NMDA antagonist for major depressive disorder and bipolar depression

Boston, MA, December 18, 2025 (Business Wire) -- PureTech Health plc announced that its Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO) and a member of the Board, effective immediately. Lyne had served as interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. His leadership priorities include advancing financing for emerging entities such as Celea Therapeutics following recent regulatory progress, while shar

Paris and Emeryville, CA, December 24, 2025 (Reuters) -- Sanofi announced it will acquire U.S.-based Dynavax Technologies in a deal valued at approximately $2.2 billion, adding an approved adult hepatitis B vaccine and a late-stage shingles candidate to its vaccines pipeline. The transaction, expected to close in Q1 2026, follows recent strategic moves by Sanofi to broaden growth beyond its blockbuster asthma treatment Dupixent, including acquisitions of Vicebio and BluePri

Houston, TX, December 17, 2025 (ACCESS Newswire) -- CNS Pharmaceuticals announced a CEO transition, with industry veteran Rami Levin appointed President and Chief Executive Officer, effective January 1, 2026, following the departure of John Climaco. Levin brings nearly three decades of global leadership experience across oncology, neurology, rare diseases, and cell and gene therapy, including scaling organizations, advancing late-stage programs, and raising capital. The boa

New Brunswick, NJ, December 29, 2025 (PR Newswire) -- Johnson & Johnson has completed its $3.05 billion all-cash acquisition of Halda Therapeutics, adding a differentiated oral oncology platform to its Innovative Medicine portfolio. The deal brings HLD-0915, a once-daily oral prostate cancer therapy designed to overcome resistance mechanisms through Halda’s proprietary RIPTAC™ technology. Beyond prostate cancer, the platform also supports earlier-stage programs across breas

San Francisco, CA, December 15, 2025 (Yahoo Finance) -- OpenAI-backed biotech startup Chai Discovery raised $130 million in a Series B financing round, pushing its valuation to $1.3 billion. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Thrive Capital, SV Angel, Emerson Collective, and others, bringing total funding to more than $225 million. Chai develops AI foundation models for drug discovery, and says its latest pla

Yardley, PA, December 5, 2025 (PR Newswire) -- Jubilant Therapeutics announced the appointment of Daniel J. O’Connor as President and Chief Executive Officer, effective December 1, 2025, as the company advances its clinical-stage oncology and autoimmune pipeline. O’Connor brings more than three decades of leadership experience in biotechnology, most recently guiding Ambrx Biopharma through a period of significant value creation that culminated in its acquisition. His prior

Brisbane, CA, December 09, 2025 (Globe Newswire) -- Vera Therapeutics announced the pricing of an underwritten public offering of just over 6.1 million Class A shares at $42.50 per share, generating approximately $261 million in gross proceeds before fees. The company also granted underwriters a 30-day option to purchase up to an additional 920,716 shares, which could further increase the total raise. Proceeds are expected to support Vera’s late-stage clinical development p